# Adicet Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adicet-bio

- Industry: Biotechnology
- Headquarters: Redwood City, US
- Website: www.adicetbio.com
- Total disclosed funding: $131M
- Latest round: Series B (Sep 2, 2019)
- Investors on record: 13

## About

Founded in 2014 and based in California, US, Adicet Bio, Inc. is a biopharmaceutical company that discovers allogeneic gamma delta T cell therapies for cancer. The company was formed by CEO Chen Schor. In November 2016, Adicet Bio, Inc. acquired Applied Immune Technologies that develops immunotherapies directed to the intracellular proteome. In September 2020, Adicet Bio, Inc. merged with resTORbio, Inc. and now operates as Adicet Bio, Inc., through which Adicet Bio, Inc. will become a publicly listed company on the NASDAQ stock exchange under the ticker symbol ACET. In January 2024, Adicet Bio, Inc. raised USD 85.19 million in a private placement, selling 27.05 million shares at USD 2.4 per share on the Nasdaq Global Select Market under the ticker symbol "ACET". Adicet Bio, Inc. has granted the underwriters a 30-day option to purchase up to an additional 5.32 million shares of common stock as part of the listing.

The company’s scientific team is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

The company’s revenue is generated by conducting clinical trials to perform tumor-killing functions.

## Funding rounds

- Series B, Sep 2, 2019, $80M — OrbiMed Advisors, Novartis Venture Fund, Johnson & Johnson Innovation, Consensus Business Group, Pontifax Venture Capital, KB Investment, DC Chemical, Samsung Venture Investment, DSC Investment, Handok Inc., aMoon, Regeneron Pharmaceuticals, Inc., SBI JI Innovation Advisory
- Series A, Jan 27, 2016, $51M — OrbiMed Advisors, Novartis Venture Fund, Pontifax Venture Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B
- Consensus Business Group — Series B
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series B
- DC Chemical — Series B
- Samsung Venture Investment (https://capitalatlas.ai/funds/samsung-venture-investment) — Series B
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series B
- Handok Inc. — Series B
- aMoon (https://capitalatlas.ai/funds/amoon) — Series B
- Regeneron Pharmaceuticals, Inc. — Series B
- SBI JI Innovation Advisory (https://capitalatlas.ai/funds/sbi-ji-innovation-advisory) — Series B